{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T09:10:06Z","timestamp":1759569006313,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":3325,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.exphem.2013.02.001","type":"journal-article","created":{"date-parts":[[2013,2,5]],"date-time":"2013-02-05T00:23:59Z","timestamp":1360023839000},"page":"462-469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia"],"prefix":"10.1016","volume":"41","author":[{"given":"Tomasz","family":"Stoklosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliza","family":"Glodkowska-Mrowka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazyna","family":"Hoser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Kielak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilona","family":"Seferynska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Wlodarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2013.02.001_bib1","first-page":"1497","article-title":"A minute chromosome in human granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.exphem.2013.02.001_bib2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2013.02.001_bib3","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2013.02.001_bib4","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment","volume":"100","author":"Roche-Lestienne","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.02.001_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/leu.2010.197","article-title":"Do we have to kill the last CML cell?","volume":"25","author":"Ross","year":"2011","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2013.02.001_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/10428194.2010.546912","article-title":"Chronic myeloid leukemia cells refractory\/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state","volume":"52","author":"Skorski","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2013.02.001_bib7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2362.2007.01892.x","article-title":"Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia","volume":"38","author":"Sillaber","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.exphem.2013.02.001_bib8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2141.2009.07657.x","article-title":"Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and\u00a0other haematological malignancies","volume":"145","author":"Teachey","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2013.02.001_bib9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.bjc.6602902","article-title":"mTOR signaling: implications for cancer and anticancer therapy","volume":"94","author":"Petroulakis","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.exphem.2013.02.001_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2013.02.001_bib11","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1017\/S1462399408000586","article-title":"Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas","volume":"10","author":"Drakos","year":"2008","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.exphem.2013.02.001_bib12","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"key":"10.1016\/j.exphem.2013.02.001_bib13","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/leu.2011.66","article-title":"Roles of the Ras\/Raf\/MEK\/ERK pathway in leukemia therapy","volume":"25","author":"Steelman","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2013.02.001_bib14","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1242\/jcs.051011","article-title":"mTOR signaling at a glance","volume":"122","author":"Laplante","year":"2009","journal-title":"J Cell Sci"},{"key":"10.1016\/j.exphem.2013.02.001_bib15","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.1038\/sj.onc.1209888","article-title":"mTOR, translation initiation and cancer","volume":"25","author":"Mamane","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2013.02.001_bib16","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2013.02.001_bib17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2013.02.001_bib18","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.exphem.2006.05.002","article-title":"Constitutive phosphorylation of\u00a0the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients","volume":"34","author":"Chow","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2013.02.001_bib19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.leu.2404471","article-title":"Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma","volume":"21","author":"Haritunians","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2013.02.001_bib20","first-page":"5716","article-title":"Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin","volume":"63","author":"Ly","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2013.02.001_bib21","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2008.27","article-title":"Targeting survival cascades induced by activation of Ras\/Raf\/MEK\/ERK, PI3K\/PTEN\/Akt\/mTOR and Jak\/STAT pathways for effective leukemia therapy","volume":"22","author":"McCubrey","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2013.02.001_bib22","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development","volume":"19","author":"Burchert","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2013.02.001_bib23","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V91.2.406","article-title":"The SH3 domain contributes to BCR\/ABL-dependent leukemogenesis in\u00a0vivo: role in adhesion, invasion, and homing","volume":"91","author":"Skorski","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.02.001_bib24","doi-asserted-by":"crossref","first-page":"9624","DOI":"10.1158\/0008-5472.CAN-08-1131","article-title":"Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells","volume":"68","author":"Konig","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2013.02.001_bib25","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.bbrc.2004.11.086","article-title":"BCR\/ABL activates Rap1 and B-Raf to stimulate the MEK\/Erk signaling pathway in hematopoietic cells","volume":"326","author":"Mizuchi","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.exphem.2013.02.001_bib26","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2013.02.001_bib27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.devcel.2007.03.020","article-title":"The two TORCs and Akt","volume":"12","author":"Bhaskar","year":"2007","journal-title":"Dev Cell"},{"key":"10.1016\/j.exphem.2013.02.001_bib28","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.4161\/cc.7.24.7244","article-title":"Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors","volume":"7","author":"Carracedo","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.exphem.2013.02.001_bib29","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/sj.leu.2403848","article-title":"Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib","volume":"19","author":"Dengler","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2013.02.001_bib30","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2013.02.001_bib31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/sj.leu.2403649","article-title":"Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease","volume":"19","author":"Eisterer","year":"2005","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2013.02.001_bib32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/10428194.2010.546920","article-title":"Mechanisms of resistance to BCR-ABL kinase inhibitors","volume":"52","author":"Diamond","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2013.02.001_bib33","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1532\/IJH97.04013","article-title":"Imatinib mesylate in combination with other chemotherapeutic agents for chronic myelogenous leukemia","volume":"79","author":"Tauchi","year":"2004","journal-title":"Int J Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2013.02.001_bib34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3109\/10428194.2010.546913","article-title":"Inhibition of autophagy: A new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors","volume":"52","author":"Calabretta","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2013.02.001_bib35","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/cncr.22901","article-title":"Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2013.02.001_bib36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/shem.2003.50035","article-title":"Towards combination target-directed chemotherapy for chronic myeloid leukemia: Role of farnesyl transferase inhibitors","volume":"40","author":"Daley","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.exphem.2013.02.001_bib37","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1182\/blood-2007-09-114454","article-title":"Potentiation of antileukemic therapies by the dual PI3K\/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells","volume":"111","author":"Weisberg","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.02.001_bib38","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.leukres.2008.07.023","article-title":"Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor","volume":"33","author":"Hirase","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2013.02.001_bib39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-8722-4-6","article-title":"BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance","volume":"4","author":"Quentmeier","year":"2011","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.exphem.2013.02.001_bib40","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.it.2009.02.002","article-title":"The multiple facets of mTOR in immunity","volume":"30","author":"Weichhart","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1016\/j.exphem.2013.02.001_bib41","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/leu.2011.67","article-title":"The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem\/progenitor cells","volume":"25","author":"Pellicano","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2013.02.001_bib42","first-page":"188","article-title":"Pharmacologic mitogen-activated protein\/extracellular signal-regulated kinase kinase\/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr\/Abl-expressing human leukemia cells","volume":"62","author":"Yu","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2013.02.001_bib43","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2013.02.001_bib44","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2011-10-385658","article-title":"Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors","volume":"119","author":"Nieborowska-Skorska","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.02.001_bib45","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.leukres.2009.07.012","article-title":"mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein","volume":"34","author":"Mancini","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2013.02.001_bib46","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.4161\/cc.8.7.8044","article-title":"Targeting mTOR with rapamycin: One dose does not fit all","volume":"8","author":"Foster","year":"2009","journal-title":"Cell Cycle"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X1300012X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X1300012X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:30:26Z","timestamp":1759566626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X1300012X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0301472X1300012X"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2013.02.001","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2013.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}